Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose pegvisomant added to long-acting somatostatin analogues in acromegaly
2011-004231-31Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegvisomant in acromegaly (2 arms), sponsored by Erasmus MC. Primary endpoint: Quality of Life change over 16 weeks. Started Oct 2011; status: active.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2011-004231-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004231-31.